大鼠肝移植的麻醉

目的研究氯胺酮在大鼠肝移植中的合适剂量.方法对100只雄性Wister大鼠行40例肝移植,观察供受体麻醉过程、药物剂量和效果. 结果供体手术氯胺酮麻醉的剂量以100～125 mg/kg合适,受体手术氯胺酮麻醉的剂量以75～100 mg/kg合适.结论在大鼠肝移植的手术中,氯胺酮是一种理想的麻醉药品.     

腰麻硬膜外联合麻醉在全产程中的镇痛效果及对母婴的影响

①目的　探讨腰麻硬膜外联合麻醉在全产程中的镇痛效果以及对母婴的影响。②方法　选择ASAⅠ～Ⅱ级、无禁忌证的单胎头位临产初产妇 30 0例 ,随机分为腰硬组 (腰麻硬膜外联合麻醉 )、硬外组 (硬膜外麻醉 )和对照组 (未用任何麻醉方法 )各 10 0例。行L2～ 3 椎间隙一点穿刺并一次成功。分别观察镇痛效果、起效时间、用药量、副作用、产程、分娩方式及母婴情况。③结果　腰硬组镇痛效果、起效时间以及用药量明显优于硬外组(uc=5 .34,t=16 .92～ 2 9.6 9,P <0 .0 1) ;与对照组比较 ,宫颈扩张加速 ,第一产程明显缩短 ,而第二产程延长 (t =3.34～ 4 8.4 9,P <0 .0 1) ,剖宫产率明显下降 ,而阴道助产率增高 ,胎儿宫内窘迫的发生率下降 (χ2 =6 .82～ 2 0 .35 ,P <0 .0 1)。④结论　腰麻硬膜外联合麻醉用于分娩镇痛优于硬膜外麻醉 ,是一种安全有效、更适合全产程镇痛的麻醉方法。     

The Application of Topical Anesthesia Combined with Subconjunctival Anesthesia for Glaucoma Surgery

Purpose: To evaluate the feasibility, reliability and analgesia effect of topical anesthesia combined with subconjunctival anesthesia in anti-glaucomatous surgery.Methods: Two hundred and four cases (357 eyes) underwent anti-glaucomatous surgeries under topical anesthesia with 0.5％ Alcaine eye drops combined with subconjunctival anesthesia with 2％ Lidocaine. The analgesic effect was analysed with visual analogue pain scale.Results: Among all of 357 eyes, 62 eyes underwent peripheral iridectomy, 67 eyes underwent simple trabeculectomy, 167 eyes underwent compound brabeculectomy and 12 eyes nonpenetrating trabecular surgery. The effects of anesthesia were as follows: 304 eyes (85.2％) were painless (Grade Ⅰ), 50 eyes (14.0％) were slight painful (Grade Ⅱ), and 3 eyes (0.8％) were more painful (Grade Ⅲ) during surgery. And no severe complications were observed in all the cases during surgery and postoperatively. Amaurosis fugax was not observed in the glaucoma patients at the late stage with narrow vi     

臂丛加强化麻醉后并发颈部抽动9例分析

目的探讨臂丛加强化麻醉后颈部抽动的原因及防治。方法对近年来在麻醉方法、用药相同,术后颈部抽动患者的观察治疗过程进行分析。结果臂丛麻醉并发颈部抽动给予充分镇静后可完全治愈。结论麻醉后并发颈部抽动为药物副作用及颈局部刺激的综合作用。     

气管内硬膜外联合麻醉下的超前镇痛

目的研究气管内硬膜外联合麻醉下,硬膜外给药时间不同、全麻诱导药物不同对术后镇痛产生的影响。方法开腹行切除肝癌、胃癌的病人120例,随机分为A、B、C、D4组,每组30例。A组:在T8-9经硬膜外注入1%利多卡因和0.25%布比卡因混合液6～8ml,再经硬膜外注入含吗啡2mg、氟哌利多2.5mg的生理盐水10ml;全身麻醉诱导药物为芬太尼3μg·kg-1,异丙酚1～1.5mg·kg-1,琥珀胆碱2mg·kg-1。B组:诱导药物中不使用芬太尼,用利多卡因1～1.5mg·kg-1代替,术中也不使用芬太尼,其余条件同A组。C组:在T8-9行硬膜外穿刺,之后行全身麻醉诱导,诱导药物为芬太尼3μg·kg-1,异丙酚2～2.5mg·kg-1,琥珀胆碱2mg·kg-1,必要时可加芬太尼2～3μg·kg-1。切皮后90min,经硬膜外注入1%利多卡因和0.25%布比卡因6～8ml,再经硬膜外注入含吗啡2mg、氟哌利多2.5mg的生理盐水10ml。D组:诱导药物中不使用芬太尼,用利多卡因1～1.5mg·kg-1代替,术中也不使用芬太尼,其余条件同C组。分别于术毕后4、8、24、48h观测VAS、镇痛药消耗量、恶心、呕吐、骚痒等指标。结果A组的药物消耗量最少、镇痛效果最好;B组和C组次之;D组的药物消耗量最大,镇痛效果最差。结论硬膜外复合气管内麻醉时,硬膜外麻醉与芬太尼同时使用,术后镇痛效果最好。     

236例无痛人工流产术的疗效观察

目的:探讨异丙酚和芬太尼混合液静脉麻醉、笑气吸入麻醉及2%利多卡因宫颈局部浸润麻醉三种镇痛方法在人工流产手术中的疗效比较。方法:自2003年8月至2004年1月对236例妇科门诊早孕要求终止妊娠的妇女实施无痛人工流产术。随机分成3组。A组:异丙酚+芬太尼静脉麻醉(85例);B组:N2O(笑气)吸入麻醉(88例);C组:2%利多卡因宫颈局部浸润麻醉(63例),观察人流术中其镇痛效果并对疼痛进行分级。结果:A组85例100%可达到完全不痛(疼痛分级为0级);B组65.90%可达到完全不痛,Ⅰ级23.86%,Ⅱ级9.09%,Ⅲ级1.15%;C组0例可达到完全不痛,Ⅰ级63.49%,Ⅱ级30.16%,Ⅲ级6.35%。结论:受术者如无心肺疾患及人流禁忌证,无痛人工流产术应选择异丙酚+芬太尼静脉麻醉可达到完全无痛,痛苦最小。     

罗哌卡因、左旋布比卡因与布比卡因低位硬膜外麻醉的比较

目的比较罗哌卡因、左旋布比卡因与布比卡因低位硬膜外麻醉的临床效果。方法60例行下腹部手术病人。随机分成三组，每组20例。Ⅰ组：0．5％罗哌卡因；Ⅱ组：0．5％左旋布比卡因；Ⅲ组：0．5％布比卡因。行连续低位硬膜外麻醉。观察感觉阻滞起效时间、感觉阻滞平面上界、运动阻滞起效时间、运动阻滞程度及麻醉质量。结果Ⅰ、Ⅱ和Ⅲ组首次局麻药用量分别为（14．38±1．57）、（14．75±0．50）和（13．80±1．30）ml。Ⅰ组运动阻滞起效时间比Ⅲ组长（P〈0．05），Ⅰ组Bromage评分为1分的例数多于Ⅲ组（P〈0．05）。与Ⅲ组比较，Ⅰ、Ⅱ组感觉阻滞起效时间、感觉阻滞平面上界差异均无统计学意义。Ⅲ组SBP在感觉阻滞平面达上界及运动阻滞起效时有明显降低（P〈0．05）。结论0．5％罗哌旨因、左旋布比卡因或布比卡因连续硬膜外麻醉均可产生良好的感觉和运动阻滞，三种药物药效学相似。     

长托宁用于全麻术前用药的效果观察

目的:观察长托宁作为全麻病人麻醉前用药对心血管系统和呼吸道分泌物的影响.方法:随机选择20例需全麻手术病人,在麻醉诱导前静注长托宁0.015 mg/kg,观察注药前、后5、10、20分钟各时点的血压、心率、脉搏氧饱和度及口干程度以及术中术毕口腔和呼吸道分泌物情况.结果:病人使用长托宁后5、10、20分钟的血压、心率与使用前相比有下降趋势,但无统计学意义(P＞0.05),脉搏氧饱和度未见明显改变,用药10分钟病人有轻度口干,术毕拔除气管导管时口腔及呼吸道分泌物较少.结论:长托宁用于全麻病人麻醉前给药效果满意.     

聚环氧氯丙烷／液晶复合富氧膜的研究

研究了聚环氧氯丙烷(PECHCH)/N(4-乙氧基苄叉)4-丁基苯胺(EBBA)复合膜对氧气和氮气的透过性和选择性。用示差扫描量热计(DSC)、解偏振光强仪(DLI和偏光显微镜考察了复合膜的形态结构。结果表明,当PECH/EBBA复合膜处于液晶的向列相转变温度时,有较高的气体透过性和选择性。发现只有复合膜中EBBA含量在30wt％以上,PECH和EBBA呈非均相混合时,才有较明显的富氧效果。当EBBA含量达50wt%时,氧氮分离系数α=3.78。     

Hemodynamic effects of KRN2391 (potassium channel opener) in halothane-anesthetized dogs

The cardiovascular responses to an infusion of KRN2391, a potassium channel opener, was studied in halothane-anesthetized dogs. Intravenous administration of KRN2391 at 1.0 and 5.0 μg·kg⁻¹·min⁻¹ for 60 min produced dose-dependent decreases in mean arterial pressure (MAP) and systemic vascular resistance (SVR) associated with dose-dependent increases in the cardiac index (CI) and stroke volume index (SVI) but was not accompanied by an increase in heart rate (HR). The maximum decrease in MAP during the infusion of KRN2391 at 1.0 and 5.0 μg·kg⁻¹·min⁻¹ was −13±7% (P<0.01) and −37±10% (P<0.01), respectively. The maximum reduction in SVR after 1.0 and 5.0 μg·kg⁻¹·min⁻¹ was −20±11% (P<0.01) and −60±16% (P<0.01), respectively. A KRN2391 infusion of 1.0 and 5.0 μg·kg⁻¹·min⁻¹ increased Cl a maximum of 11±13% (P<0.05) and 65±33% (P<0.01), respectively. KRN2391 1.0 μg·kg⁻¹·min⁻¹ showed a tendency to increase SVI but this change was not significant, KRN2391 5.0 μg·kg⁻¹·min⁻¹, however, produced a significant increase in SVI. The present results demonstrate that the decrease in MAP and the increases in CI and SVI caused by KRN2391 are due to a reduction in the afterload. Therefore, we conclude that these cardiovascular profiles of KRN2391 may be benificial in perioperative uses including the control of systemic blood pressure and the treatment of hypertension during halothane anesthesia in clinical practice.